Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: A clinical report
Fifty-seven patients with MAGE-3-positive measurable metastatic cancer, most of them with melanoma, were vaccinated with escalating doses of a recombinant MAGE-3 protein combined with a fixed dose of the immunological adjuvant SBAS-2, which contained MPL and QS21. The immunisation schedule included 4 intramuscular (i.m.) injections at 3-week intervals. Patients whose tumour stabilised or regressed after 4 vaccinations received 2 additional vaccinations at 6-week intervals. The vaccine was generally well tolerated. Among the 33 melanoma patients who were evaluable for tumour response, we observed 2 partial responses, 2 mixed responses and 1 stabilisation. Time to progression in these 5 patients varied from 4 to 29 months. In addition, a partial response lasting 10 months was observed in 1 of the 3 metastatic bladder cancer patients included. None of the tumour responses described above involved visceral metastases. Immunological responses to the vaccine will be reported separately.
|Keywords||Antibodies, Cancer, Immunological adjuvant SBAS-2, Immunotherapy, MAGE-3 protein, Melanoma, T lymphocyte|
|Persistent URL||dx.doi.org/10.1016/S0959-8049(02)00479-3, hdl.handle.net/1765/70176|
|Journal||European Journal of Cancer|
Marchand, M.A, Punt, C.J.A, Aamdal, S, Escudier, B, Kruit, W.H.J, Keilholz, U, … Stoter, G. (2003). Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: A clinical report. European Journal of Cancer, 39(1), 70–77. doi:10.1016/S0959-8049(02)00479-3